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Chagas disease is initiated upon infection by Trypano-
soma cruzi. Among the health consequences is a decline
in heart function, and the pathophysiological mecha-
nisms underlying this manifestation are not well under-
stood. To explore the possible mechanisms, we em-
ployed IgY LC10 affinity chromatography in conjunction
with ProteomeLab PF2D and two-dimensional gel elec-
trophoresis to resolve the proteome signature of high
and low abundance serum proteins in chagasic patients.
MALDI-TOF MS/MS analysis yielded 80 and 14 differen-
tially expressed proteins associated with cardiomyopa-
thy of chagasic and other etiologies, respectively. The
extent of oxidative stress-induced carbonyl modifica-
tions of the differentially expressed proteins (n  26)
was increased and coupled with a depression of antiox-
idant proteins. Functional annotation of the top net-
works developed by ingenuity pathway analysis of
proteome database identified dysregulation of in-
flammation/acute phase response signaling and lipid
metabolism relevant to production of prostaglandins
and arachidonic acid in chagasic patients. Overlay of the
major networks identified prothrombin and plasminogen
at a nodal position with connectivity to proteome signa-
ture indicative of heart disease (i.e., thrombosis, angio-
genesis, vasodilatation of blood vessels or the aorta,
and increased permeability of blood vessel and endo-
thelial tubes), and inflammatory responses (e.g., platelet
aggregation, complement activation, and phagocyte ac-
tivation and migration). The detection of cardiac pro-
teins (myosin light chain 2 and myosin heavy chain 11)
and increased levels of vinculin and plasminogen pro-
vided a comprehensive set of biomarkers of cardiac
muscle injury and development of clinical Chagas dis-
ease in human patients. These results provide an impe-
tus for biomarker validation in large cohorts of clinically
characterized chagasic patients. Molecular & Cellular
Proteomics 11: 10.1074/mcp.M112.017640, 435–452,
2012.
Chagas disease continues to present a serious threat to
human health in Latin America and is one of the most impor-
tant emerging parasitic diseases in developed countries in-
cluding the United States (1). According to a World Health
Organization report released in 2010, an estimated 10 million
people are infected, and 25 million people are at risk of
infection in endemic countries (2). It is assessed that
300,000 infected patients live in the United States (3). Up to
40% of chronically infected individuals develop cardiac alter-
ations, and up to 10% develop digestive, neurological or
mixed alterations, resulting in considerable morbidity and
mortality (4).
Human plasma and serum are the most easily available,
clinically valuable specimens. Besides abundant proteins,
e.g., albumin, immunoglobulin, transferrin, haptoglobin, and
lipoprotein, plasma and serum contain many other proteins
that are secreted or released from cells and tissues through-
out the body. In chronic conditions or disease states, as is
also noted in chagasic patients (5, 6), modification of the
proteome manifests as a result of disease-associated
changes in specific genes up- or down-regulation, isoform
switching, or de novo protein synthesis (7, 8). Further, pro-
gression of disease severity, presented by an increasing order
of cardiac injury and cell death (9, 10), may also result in the
release of intracellular proteins in the peripheral system, thus
altering the proteome profile. It is thus logical to assume that
the pathological processes during the development of Cha-
gas disease would cause characteristic changes in the circu-
lating proteins and generate a detectable, disease-specific
molecular phenotype.
In addition to changes in proteome profile, post-transla-
tional protein modifications in response to disease-associated
stress also contribute to protein change resulting from mod-
ification of specific amino acids. We have documented in
experimental animal models and human chagasic patients
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that reactive oxygen species (ROS)1 of inflammatory and mi-
tochondrial origin contribute to oxidative modification of pro-
teins in peripheral blood and myocardium (11–14). For exam-
ple, treatment of infected animals with an antioxidant was
effective in arresting oxidative cardiac pathology (15) and
preventing the loss of cardiac left ventricular function in
chronic hearts (16), thus establishing the pathological signif-
icance of oxidative overload in Chagas disease. To date,
however, proteomic examples of oxidative modification iden-
tification in cardiovascular diseases are lacking.
The plasma/serum proteome is the most useful version of
the human proteome for clinical investigations and patient
diagnostic and treatment purposes. Nevertheless, clinical
proteomics, i.e., translation of proteomic techniques to study
clinical pathology, has not been widely used. The two-dimen-
sional polyacrylamide gel electrophoresis (2D-GE) method
enables identification of major proteins in a tissue or subcel-
lular fraction by mass spectrometric methods and can be
used to compare quantities of proteins in related samples
(17). However, 2D-GE has many drawbacks, including a nar-
row dynamic range that requires the multistep removal of
abundant proteins before low abundance serum proteins or
biomarkers can be detected, problematic solubilization and
separation of hydrophobic proteins, and a restricted ability to
load limited sample amounts on a gel (250 g) (18). Poor
reproducibility of gel images between experiments, imprecise
quantitation, and intensive labor requirements are additional
limitations in applying the 2D-GE approach for clinical pro-
teome analysis (19).
The ProteomeLabTM PF2D system offers an alternative ap-
proach to protein profiling that addresses issues of complex-
ity and utilization of fractions after analysis. PF2D is designed
to allow automated separation of proteins in the first dimen-
sion by pI-based chromatofocusing, followed by a second
dimension hydrophobicity-based separation of proteins by
reverse phase (RP)-HPLC (20). Changing the composition or
pH range of elution buffer allows increased resolution of hy-
drophobic, basic, or acidic proteins, a process that cannot be
achieved by 2D-GE (21). Importantly, all protein fractions from
PF2D are collected in 96-well plates from which they can be
easily lyophilized and submitted for mass spectrometric pro-
tein/peptide identification or utilized for immunoblotting, cat-
alytic staining, or other assays. The in-built scanning spectro-
photometer allows one to simultaneously monitor the normal
and oxidatively modified isoforms of the proteins in second
dimension fractions for the automated, efficient detection of
disease-associated protein oxidative and other (e.g., phos-
phorylation) modifications (22).
In this study, we investigated the host physiological and
pathological changes at the protein level in chagasic human
patients. We employed IgY-12 chemistry to separate the se-
rum-abundant proteins and the PF2D system to develop the
protein signature of low abundance serum proteins in Chagas
disease patient samples. We also made use of traditional one-
and two-dimensional gel electrophoresis and ELISA to iden-
tify serum-abundant proteins that were differentially ex-
pressed or oxidized in chagasic patients. Our findings of a
number of proteins that were differentially expressed in pa-
tients provide clues to the pathomechanisms that contribute
to Chagas disease.
MATERIALS AND METHODS
Human Subjects—Human sera samples from chagasic and non-
chagasic/other cardiomyopathy patients used in this study were ob-
tained from Salta, Argentina and Chiapas, Mexico. Sera samples from
seronegative healthy individuals exhibiting no history or clinical symp-
toms of cardiac disease from the same geographical area were used
as controls. All of the procedures were approved by the institutional
review boards at the University of Texas Medical Branch, Universidad
Nacional de Salta, Argentina, and the Universidad Auto´noma de
Chiapas, Mexico.
In Argentina, written informed consent was obtained from all indi-
viduals (age range: 19–71 years, 56% females) before their enrollment
in the study. Venous blood samples were collected without antico-
agulant to obtain serum. Trypanosoma cruzi-specific antibodies in
sera samples were monitored by an enzyme-linked immunosorbent
assay using a Wiener Chagatest-ELISA recombinant v.4.0 kit com-
prising six recombinant proteins known to be expressed in mamma-
lian stage of T. cruzi in isolates circulating in Latin America. Briefly,
96-well plates were coated with recombinant proteins and then se-
quentially incubated with 20-l sera samples (1:20 dilution) and
horseradish peroxidase-conjugated human monoclonal anti-IgG and
color-developed with chromogenic substrate monitored by spec-
trometry at 450 nm (cutoff value: average of seronegative samples
(0.1 optical density)  0.2 optical density, i.e., 0.3). Serological
tests were also done following the specifications of the commercial
Indirect Heamagglutination test kit (Wiener Chagatest-HAI). Briefly,
sera samples (25-l 4-fold dilutions) were mixed with red blood cells
sensitized with T. cruzi cytoplasmic and membrane antigens and
agglutination-monitored. The titer was defined as the highest serum
dilution presenting agglutination (positive 1:16 dilution). Those pos-
itive by both tests were identified as seropositive. The clinical data
included medical history, physical examination, subjective complaint
of frequency and severity of exertional dyspnea, 12-lead electrocar-
diography at rest to obtain a comprehensive view of cardiac rhythm
and conduction abnormalities, 3-lead electrocardiography with exer-
cise to note major cardiac rhythm alterations, transthoracic echocar-
diogram to obtain objective information regarding the left ventricular
contractile function, and chest x-ray to assess cardiomegaly (cardio-
thoracic ratio  0.5). The severity of exertional dyspnea was graded
according to the New York Heart Association classification (23).
Based on these criteria, seropositive chagasic patients exhibiting no
echocardiographic abnormalities, preserved systolic function (ejec-
tion fraction  55%), and no left ventricular dilatations, but with
negligible to minor electrocardiography alterations were graded as
clinically asymptomatic. Seropositive patients were graded clinically
symptomatic if they exhibited varying degrees of systolic dysfunction
1 The abbreviations used are: ROS, reactive oxygen species; 2D-
GE, two-dimensional gel electrophoresis; CC, cardiomyopathy of
chagasic origin; CO, cardiomyopathy of other etiologies; DNPH, 2,4-
dinitrophenylhydrazine; IPA, Ingenuity pathways analysis; IPG, immo-
bilized pH gradient; MYH11, myosin heavy chain 11; MYL2, myosin
light chain 2; NN, normal subjects with no disease; PLG, plasmino-
gen; RP, reverse phase; VCL, vinculin; VIM, vimentin; WB, Western
blotting.
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(ejection fraction 40–54% or less) and/or left ventricular dilatation
(end diastolic diameter  57 mm). Seronegative cardiomyopathy
patients of other etiologies (CO) were categorized by criteria similar to
those of the chagasic patients. Seronegative, healthy controls were
recruited from the same geographical area.
In Mexico, human sera samples (age range: 18–73 years, 55%
females) were collected within the framework of a research project on
emerging zoonotic diseases conducted jointly by several institutions,
including Chiapas State University, Mexican Social Security Institute,
Chiapas Health Institute, and University of Texas Medical Branch at
Galveston. All of the samples were screened by ELISA, flow cytom-
etry, and Stat-Pak (Chembio Diagnostic Systems, Medford, NY) to
distinguish seropositive and seronegative samples before inclusion in
the study (24). The seropositive subjects generally represented the
indeterminate/asymptomatic form of the disease.
Separation of High Abundance Sera Proteins—To enrich the low
abundance proteins for enhanced detection, we employed the IgY-12
high capacity LC10 proteome partitioning system (Beckman Coulter,
Brea, CA) in combination with the ProteomeLab PF2D system (Beck-
man), according to the manufacturer’s instructions (details in supple-
mental File 1). The collected low abundance proteins in the flow
through fractions consisted of 4.8–10% of the proteins present in the
original whole serum, and 90–95.2% of the total proteins were cap-
tured as major (abundant) proteins by IgY columns. To obtain suffi-
cient quantities of low abundance proteins for PF2D analysis, we
processed five aliquots (total 1250 l) of each sera sample by IgY-12
chromatography. The flow through (enriched low abundance proteins)
and eluted (high abundance proteins) serum fractions were neutral-
ized, concentrated by using Amicon ultracentrifugal filters (3-kDa
cutoff; Millipore), and desalted by PD-10 desalting columns (GE
Healthcare). Protein content was determined by using the Bradford
assay (Bio-Rad).
Protein Profiling by ProteomeLab PF2D System—Serum protein
fractionation using PF2D system was carried out by high performance
chromatofocusing in the first dimension and RP-HPLC in the second
dimension. Briefly, after equilibration, the samples (2.5 mg of protein
in 100 l) were injected onto the chromatofocusing column, and first
dimension fractionation was performed using a pH gradient 8.3–3.5,
the fractions being collected with the fraction collector/injector mod-
ule at 0.3-pH intervals. For the second dimension separation, se-
lected first dimension fractions (250 l) were injected into the RP-
HPLC column and run for 2 min with solvent A (0.1% trifluoroacetic
acid in HPLC water). The column was then eluted with a linear
gradient of 0–100% solvent B (0.08% trifluoroacetic acid in acetoni-
trile) for 33 min, and second dimension fractions were collected at
30-s intervals in 96-well plates.
ProteoVue software (Eprogen) was utilized to convert chromato-
graphic intensities of fractions collected after a second dimension
RP-HPLC fractionation of each of the first dimension fractions col-
lected in pH gradient 8.3–4.0. This analysis produced a highly de-
tailed heat map of each sample, incorporating the dimensions of pI (x
axis) and hydrophobicity (y axis). DeltaVue software was employed to
compare derived intensity bands from ProteoVue analysis of any two
samples, allowing quantitative differences in protein contents mea-
sured by peak area (volume). Finally, Karat 32 software was employed
to compare significantly different peaks among multiple samples and
to identify proteins. Detailed methods for protein profiling by PF2D
and comparative proteome analysis are presented in supplemental
File 1.
Profiling of High Abundance Serum Proteins by Two-dimensional
Gel Electrophoresis—We rehydrated 11-cm immobilized pH gradient
(IPG) strips (pH 3–10, pH 4–7, or pH 7–10 [from Bio-Rad]) at 50 V for
12 h in 250 l of rehydration buffer (1 M thiourea, 8 M urea, 2%
CHAPS, 1% dithiothreitol, and 0.2% ampholytes (Bio-Rad)) contain-
ing 200 g of protein sample (n 4/sample) and 0.002% of bromphe-
nol blue. Isoelectric focusing was performed at 500 V for 1 h, 1000 V
for 1 h, 8000 V for 2 h, and then 8000 V for a total of 50,000 Vh (25).
The IPG strips were suspended in equilibration buffer (50 mM Tris-
HCl, pH 6.8, 6 M urea, 20% glycerol) and sequentially incubated for 15
min each in the presence of 2% DTT, 2% SDS (reducing conditions)
and 2.5% iodoacetamide, 2% SDS (alkylating conditions). Equili-
brated IPG strips were subjected to second dimension electrophore-
sis by using 8–10% linear gradient precast Tris-HCl gels (Bio-Rad) on
a PROTEAN plus Dodeca cell system at 75 V for 1 h and then at 120
V until the dye front reached the bottom of the gel. The gels were fixed
in 10% methanol, 7% acetic acid, stained with SYPRO Ruby (Bio-
Rad), destained in 10% ethanol, 7% acetic acid, and imaged by using
a high resolution ProXPRESS proteomic imaging system (PerkinElmer
Life Sciences).
In total, 12 Sypro Ruby-stained two-dimensional gels (n  18/
group) were digitalized on a ProXPRESS proteomic imaging system
(PerkinElmer Life Sciences), and the images were analyzed on Pro-
genesis SameSpotstTM software 2.0 (NonLinear Dynamics). Normal-
ized spot volumes, i.e., the volume of each spot over the volume of all
spots in the gel, were used for comparison of the different groups,
and candidates were identified as protein spots that changed in
expression level by 2-fold as compared with normal controls. Sta-
tistical significance was assessed by the analysis of variance test, and
p values of 0.05 were considered significant for comparison (26).
Detection of Carbonyl Proteins—We employed Western blotting
(WB) in conjunction with one- or two-dimensional gel electrophoresis
to detect the carbonyl modifications in low abundance and high
abundance protein sera fractions, respectively (27, 28) (supplemental
File 1).
Mass Spectrometry and Protein Identification—Please see supple-
mental File 1 for detailed methods for processing of fractionated
protein samples collected after second dimension PF2D analysis and
protein containing gel spots from two-dimensional gels. Peptide mix-
tures (1 l) obtained after tryptic digestion were directly spotted onto
a MALDI-TOF MS/MS target plate with 1 l of -cyano-4-hydroxy-
cinnamic acid matrix solution (5 mg/ml in 50% acetonitrile). Peptides
were analyzed by using a MALDI-TOF/TOFTM ABI 4800 proteomics
analyzer (Applied Biosystems). The Applied Biosystems software
package included the 4000 Series Explorer (v. 3.6 RC1) with Oracle
Database Schema Version (v. 3.19.0) and Data Version (3.80.0) to
acquire and analyze MS and MS/MS spectral data. The instrument
was operated in a positive ion reflectron mode with the focus mass
set at 1700 Da (mass range, 850–3000 Da). For MS data, 1000–2000
laser shots were acquired and averaged from each protein spot.
Automatic external calibration was performed by using a peptide
mixture with the reference masses 904.468, 1296.685, 1570.677, and
2465.199. Following MALDI MS analysis, MALDI MS/MS was per-
formed on several (5–10) abundant ions from each protein spot. A
1-kV positive ion MS/MS method was used to acquire data under
post-source decay conditions. The instrument precursor selection
window was 3 Da. Automatic external calibration was performed by
using reference fragment masses 175.120, 480.257, 684.347,
1056.475, and 1441.635 (from precursor mass 1570.700).
Applied Biosystems GPS ExplorerTM (v. 3.6) software was em-
ployed in conjunction with MASCOT (v.2.2.07) to search the NCBI
human protein database (last accessed January 25, 2011; 17,148,519
entries) by using both MS and MS/MS spectral data for protein
identification. Protein match probabilities were determined by using
expectation values and/or MASCOT protein scores. The MS peak
filtering included the following parameters: a mass range of 800–3000
Da, minimum Signal-to-Noise filter  10, mass exclusion list toler-
ance  0.5 Da, and mass exclusion list for some trypsin and keratin-
containing compounds included masses of 842.51, 870.45, 1045.56,
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1179.60, 1277.71, 1475.79, and 2211.1 Da. The MS/MS peak filtering
included the following parameters: minimum S/N filter  10, maxi-
mum missed cleavages  1, fixed modification of carbamidomethyl,
variable modifications caused by oxidation, precursor tolerance 0.2
Da, MS/MS fragment tolerance  0.3 Da, mass  monoisotopic, and
peptide charges  1. The significance of a protein match, based on
the peptide mass fingerprint in the MS and the MS/MS data from
several precursor ions, is presented as expectation values (p 
0.001). To confirm the identified proteins were of human and not of
parasite origin, we also performed a similar search against NCBI
nonredundant protein database consisting of T. cruzi sequences.
Functional Analysis—All data sets were assessed by using an
online tool (http://www.uniprot.org/uniprot, UniProt release February
8, 2011) to predict the Gene Ontology and recognize the function of
the identified proteins. Ingenuity pathways analysis (IPA, Ingenuity
Systems) was performed to integrate the identified proteins into
networks and signaling pathways with biological meaning and signif-
icance. IPA was also employed to rapidly gain biological insight and
access a comprehensive overview of scientific findings including
biological functions, molecular interactions, regulatory events, and
pharmacological relevance. An e-value was calculated by estimating
the probability of a random set of proteins having a frequency of
annotation for that term greater than the frequency obtained in the
real set, and a threshold of 103 was set to retrieve significant
molecular functions and biological processes. With these parameters,
we were able to highlight the most informative and significantly over-
represented Gene Ontology terms in the data set (29).
Sera Screening for Detection of Disease Biomarkers—The 96-well
microtiter plates were coated overnight at 4 °C with 100-l sera
samples in 0.1 M carbonate buffer, pH 9.6 (1:50, v/v), and blocked for
2 h at room temperature with 1% nonfat dry milk. The plates were
then sequentially incubated with 100 l each of antibodies against
MYL2, VCL, and VIM (Santa Cruz, 1:3000) for 2 h, horseradish per-
oxidase-labeled IgG antibody (Southern Biotech, 1:5000) for 1 h, and
Sure blue TMB substrate for 15 min. The reaction was blocked with 2
N sulfuric acid and colorimetric change in absorbance was measured
at 450 nm on a SpectraMax 190 microplate reader (Molecular De-
vices). The ELISA results were normalized to total protein concentra-
tion, determined by Bio-Rad protein assay. Plasminogen levels were
measured using a sandwich ELISA kit from ICL Inc.
RESULTS
Immunodepletion of High Abundance Proteins in Serum—
Compared with other sample types such as bronchial lavage,
cerebrospinal fluid, and tears, plasma/serum consist of a wide
dynamic range of protein concentration, and the high abun-
dance proteins interfere with the detection of low abundance
potential biomarker proteins (30, 31). To enhance our ability to
detect low abundance proteins, we employed IgY-12 LC10
immunoaffinity columns and performed HPLC to separate
high abundance proteins. Shown in Fig. 1 (A–D) are repre-
FIG. 1. Immunodepletion of human
sera samples. A–D, human sera (250 l)
samples were partitioned by using Pro-
teomeLab IgY-12 column chromatogra-
phy at an absorbance of 280 nm to re-
move the 12 high abundance proteins.
The enriched pool of low abundance
proteins (fraction a, 5–22 min) and the
high abundance proteins bound to the
column (fraction b, 30–50 min) were col-
lected for further analysis. E, shown is
SDS-PAGE analysis of fractions a and b
collected from sera samples of normal
subjects with no disease (NN, lanes
1–6), patients with cardiomyopathy of
other etiologies (CO, lanes 7–12), and
seropositive chagasic subjects from
Mexico (CCM, lanes 13–18) and Argen-
tina (CCA, lanes 19–24).
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sentative IgY-12 LC10 affinity chromatographs of sera sam-
ples from normal subjects with no disease (NN), seronegative
individuals exhibiting cardiomyopathy of other etiologies (CO),
seropositive (clinically asymptomatic) subjects from Mexico
(CCM), and chagasic (clinically symptomatic) patients from
Argentina (CCA). The distinct separation of flow through frac-
tions (5–25 min, marked a) enriched in low abundance pro-
teins and column-bound high abundance proteins (eluted
during 30–50 min, marked b) indicate that serum low abun-
dance proteins were effectively depleted of high abundance
proteins by IgY-12 LC10 column chromatography. Polyacryl-
amide gel analysis (Fig. 1E) confirmed the above results and
showed the abundant proteins, e.g., transferrin, albumin, fi-
brinogen, and haptoglobin, were separated in the bound frac-
tion and not detectable in the low abundance protein fraction
for all sera samples.
PF2D/Mass Spectrometric Analysis of Serum Proteomic
Signature of Low Abundance Proteins in Chagasic Pa-
tients—We examined the reproducibility of the PF2D system
by submitting enriched sera samples from normal healthy
subjects to first dimension high performance chromatofocus-
ing on different days (supplemental Fig. S1A) and then sub-
mitted triplicates of first dimension fractions for second di-
mension RP-HPLC analysis (supplemental Fig. S1B). We
observed high reproducibility of retention time for both first
and second dimension fractions collected for the same and
diverse sera samples on different days and obtained precise
alignment of peaks among replicate runs. These data showed
that it is feasible to resolve complicated protein mixtures with
high reproducibility by using the ProteomeLab PF2D system.
For identifying disease-specific serum profiles, we injected
2.5 mg of each enriched sera sample into the first dimension
column. In general, for normal subjects as well as patient
groups, we recovered 30% of proteins in the 8.3–3.5 pH
gradient, 31% before the initiation of the pH gradient
(pH8.0), and the remaining 39% eluted when the column was
finally washed with high salinity buffer (supplemental Fig. S2).
We concentrated on 16 fractions collected in the pH 8.3–3.5
range gradient, which were subjected to a second dimension by
using RP-HPLC. Representative virtual two-dimensional gel
images of sera proteome of normal, chagasic, and other car-
diomyopathy subjects, combining the first and the second di-
mension and viewing proteins separated by pI and hydro-
phobicity, are shown in Fig. 2. By using the paired peak function
in DeltaVue mapping tools, we aligned and analyzed the second
dimension chromatograms for each first dimension fraction of
two groups for quantitative and qualitative analysis (supplemen-
tal Fig. S3A). A composite MultiVue comparison of peaks during
the second dimension fractionation of first dimension fractions
(supplemental Fig. S3B) clearly indicated that the shift in reten-
tion time for any particular peak among the four groups was less
than 10 s and confirmed that we could provide reliable com-
parative analysis of the second dimension peaks from different
samples based upon retention time.
DeltaVue is limited in the simultaneous analysis of more
than two samples. We therefore utilized the functions of Karat
FIG. 2. PF2D two-dimensional heat
maps. Sera samples, enriched in low
abundance proteins, were subjected to
PF2D analysis. PF2D first dimension
separation is based on pI, and second
dimension separation utilizes reverse
phase-HPLC. Shown are PF2D Prote-
oVue heat maps of representative serum
samples from normal subjects with no
disease (NN) (A), patients exhibiting car-
diomyopathy of other etiologies (CO) (B),
and seropositive, chagasic subjects
from Mexico (CCM) (C) and Argentina
(CCA) (D). ProteoVue displays the pI for
first dimension fractions on the x axis
and the second dimension retention time
as the y axis. The color scheme ranges
from purple (low absorbance) to red
(high absorbance) and indicates the pro-
tein band intensity, measured at 214 nm.
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32 software to generate and overlay second dimension pro-
tein UV traces of multiple samples. Representative second
dimension protein UV traces (214 nm) of the first dimension
fractions collected at pH 0.3 intervals during the pH 8.0–8.3
gradient for normal, chagasic, and other cardiomyopathy pa-
tient samples are shown in Fig. 3 and supplemental Fig. S4.
The comparative analysis of second dimension UV traces of
first dimension fractions collected at a pH gradient of 8.0,
4.0 and between 4–8.3 showed that a majority of peaks
were generated from first dimension fractions collected at
the pH 4–8.3 gradient, and there was no statistically signif-
icant difference in the number of total peaks (range: 1285–
1688) generated for samples from different groups (supple-
mental Fig. S5, A–D). Of these, the percentage of matching
protein peaks among different groups was 85%, demon-
strating an extensive homology in the protein profile of
cardiomyopathy patients of chagasic or other etiologies
with that of normal subjects. The differentially expressed
protein peaks detected in normal controls, seropositive
subjects from Mexico, chagasic patients from Argentina,
and other cardiomyopathy patients from Argentina, marked
with color-coded arrows in Fig. 3 and supplemental Fig. S4,
were 27  1.3, 76  6.1, 82  4.5, and 57  5, respectively.
These data indicated that (a) some sera proteins, i.e., those
that were differentially expressed in normal subjects, were
depressed in chagasic patients’ sera, and (b) chagasic pa-
tients exhibited a higher rate of differentially expressed
proteins than noted in patients with cardiomyopathy of
other etiologies.
Toward discovery of proteins that are of potential signifi-
cance in characterizing the disease state and severity, our
next task was the identification of differentially expressed
protein peaks by mass spectrometry. For this, selected sec-
ond dimension fractions were either directly subjected to
MALDI-TOF MS analysis or further resolved on 8% acrylam-
ide gels to visualize the differences in the polypeptide com-
position, and gel slices containing differentially expressed
protein bands were submitted for MALDI-TOF MS identifica-
tion. The inset in Fig. 3 shows a typical SDS-PAGE analysis of
a second dimension fraction from chagasic patients. The
protein peaks for sequencing were chosen based upon their
maximal differential expression (2-fold) in seropositive, cha-
gasic groups as compared with normal subjects. The MS and
MS/MS spectral data were submitted to the UniProt human
proteome database for identification of proteins, and then
homology searches were conducted against NCBI and
SwissProt databases to validate protein identity. These anal-
yses yielded 108 protein identifications with high probability,
some of which were identified more than once. Overall, we
identified 16, 13, and 64 low abundance proteins that were
overexpressed in normal subjects (i.e., decreased in chagasic
subjects), other cardiomyopathy patients, and chagasic pa-
tients, respectively (Table I).
2D-GE/Mass Spectrometric Analysis of Serum Proteomic
Signature of High Abundance Proteins in Chagasic Patients—
The high abundance serum proteins, eluted from the IgY-12
columns, were resolved by 2D-GE to obtain a disease-spe-
cific abundant protein signature. In initial analysis, when using
FIG. 3. Comparative analysis of ProteomeLab second dimension fractionation of low abundance sera proteins from chagasic and
other cardiomyopathy subjects. Sera samples enriched in low abundance proteins from normal subjects (NN, red), patients exhibiting
cardiomyopathy of other etiologies (CO, black), and seropositive chagasic (CC) individuals from Argentina (CCA, blue) and Mexico (CCM, green)
were subjected to first dimension pH gradient (pH 8.3–3.5), and fractions were collected at 0.3-pH intervals. The first dimension fractions were
then subjected to second dimension RP-HPLC. Shown are the representative second dimension protein UV traces (214 nm) of the first
dimension fraction collected at pH 8.0–8.3. For clarity, the UV traces were staggered by 0.005 mAu (absorbance unit). Comparative second
dimension protein UV traces (214 nm) of the first dimension fractions collected at pH 0.3 intervals during pH 8.0–3.5 gradient are shown in
supplemental Fig. S4. Inset, fourth dimension resolution of PF2D second dimension fractions from a seropositive/chagasic subject on an 8%
reducing polyacrylamide gel, stained with Coomassie Brilliant Blue G-250.
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pH 3–10 and pH 4–9 IPG strips, high abundance sera proteins
resolved in the middle portion or on the acidic side of the
second dimension 8–16% gradient gel (supplemental Fig. S6,
A and B). The narrow range IPG strips (pH 4–7) provided an
enhanced resolution of high abundance sera proteins and
detection of 5-fold more spots than were detected by using pH
3–10 and pH 4–9 IPG strips (supplemental Fig. S6C). We there-
fore used pH 4–7 IPG strips for further analysis of high abun-
dance protein sera fractions of normal controls, seropositive
chagasic subjects, and cardiomyopathy patients of other etiol-
ogies. High abundance protein fractions were pooled (three
subjects/sample), and at least six samples/group were resolved
to obtain 6 gel replicas per group. Representative gel images for
each group are shown in Fig. 4 (A–D). Gel images were aligned
by using Progenesis SameSpotsTM, and densitometric analysis
was performed to select differentially expressed protein spots
(Fig. 4E). MALDI-TOF MS/MS analysis of 32 protein spots that
were differentially expressed in chagasic patients by5-fold as
compared with normal controls (pANOVA  0.01) yielded 71
protein identifications (Table II). Further, we identified 14 low
abundance proteins that partitioned with high abundance pro-
teins in a disease-specific manner (Table II).
Carbonyl Proteome Profile in Chagas Patients—In prior in-
vestigations in our lab, we have shown that the progression of
Chagas disease is associated with pathologic oxidative
stress. To investigate whether oxidative protein modifications
elicit a disease specific serum carbonyl proteome, we incu-
bated the high and low abundance protein sera fractions with
DNPH and then performed one-dimensional gel electropho-
resis/immunoblotting to detect the DNPH-derivatized car-
bonyl proteins (supplemental Fig. S7). These data showed
that a large number of low abundance (supplemental Fig.
S7A) sera proteins in seropositive/chagasic and other car-
diomyopathy subjects were oxidized when compared with
those noted in normal controls. The extent of high abundance
protein oxidation was more pronounced in chagasic subjects
than that noted in other cardiomyopathy patients (supplemen-
tal Fig. S7B). To facilitate the identification of oxidized pro-
teins, sera fractions containing high abundance proteins were
resolved by 2D-GE, and WB was performed by using anti-
DNPH antibody (Fig. 5, A–C). Comparisons of 2D/WB mem-
brane images identified numerous oxidatively modified pro-
tein spots in high abundance protein sera fractions from
chagasic and other cardiomyopathy subjects (Fig. 5). We also
found through comparative analysis of signal densities from
SYPRO Ruby-stained gels (Fig. 4) and Western blotting im-
ages (Fig. 5) that a majority of oxidized proteins in high abun-
dance protein sera fractions from chagasic subjects were also
differentially expressed. In addition to several of the high
abundance proteins (albumin, transferring, IgH, IgL), we sub-
mitted six protein spots that were oxidized in chagasic sam-
ples (marked by arrows, Fig. 5C) to MALDI-TOF MS/MS anal-
ysis for protein identification. Oxidized proteins are marked by
footnote a in (Table II).
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For the identification of oxidized proteins in low abundance
protein-enriched sera fractions, second dimension protein
fractions from PF2D analysis were resolved on 8% acrylamide
gels, and WB was performed with anti-DNPH antibody.
Shown in Fig. 5D is a typical SDS-PAGE/WB analysis of
ProteomeLab second dimension fractions from a seroposi-
tive/chagasic subject. Corresponding Sypro Ruby-stained
gels (shown as inset in Fig. 3) were utilized to cut gel slices for
MALDI-TOF MS analysis and identification of oxidized low
abundance sera proteins. These analyses led to identification
of 33 oxidatively modified, low abundance proteins in cha-
gasic subjects as compared with normal controls (listed in
Table I).
IPA Network Analysis of the Disease-associated Proteome
Signature—The differentially expressed (or oxidized) protein
data sets (Tables I and II) were submitted to IPA and UniProt
for identifying cellular localization and molecular and biologi-
cal function. As expected for sera, 42% of the proteins
differentially expressed in chagasic patients were extracellular
(supplemental Fig. S8). Detection of the increased release of
proteins belonging to cellular compartments, including the
cell cytoplasm (13%) and nucleus (10%) in chagasic sera
(supplemental Fig. S8) indicated that T. cruzi-induced cellular
events and cell injury/cell death, and the resultant release of
intracellular proteins, at least partially, contribute to disease-
specific differential sera proteomes.
Following IPA analysis of the differentially expressed pro-
teins in cardiomyopathy patients, we identified four major
associated networks (supplemental Table S1). These includ-
ed: 1) cellular assembly and organization related to cardio-
vascular diseases (22 proteins, supplemental Fig. S9.1); 2)
cardiovascular system development and function (20 pro-
teins, supplemental Fig. S9.2); 3) lipid metabolism, molecular
transport and small molecule biochemistry (12 proteins, sup-
plemental Fig. S9.3); and 4) tissue development, gene expres-
sion, cardiovascular disease (10 proteins, supplemental Fig.
S9.4). Overlay of the associated networks (supplemental Ta-
ble S1) identified CLU, KNG1, and PLG as central nodes
(supplemental Fig. S9.5). Functional analysis by IPA identified
that 29 of the differentially expressed proteins, including 14 of
the 22 proteins linked to cellular assembly and organization
related to cardiovascular diseases network, were responsible
for elicitation of inflammation and an immune response (sup-
plemental Table S2). These included molecules indicative of
changes in activation of leukocytes (C4B, F2, GC, IGHG1,
IGHG3, KNG1, PLG, PRL, and SERPING1), a quantity of
phagocytes (BCL2A1, GCNT1, MYH11, PLG, PRL, and TF),
movement, migration, and activation of phagocytes or neu-
FIG. 4. 2D-GE analysis of serum
fractions containing high abundance
proteins. A–D, IgY-12 high capacity
LC10 proteome partitioning system was
employed to fractionate high abundance
sera proteins from normal subjects ex-
hibiting no disease (A), patients exhibit-
ing cardiomyopathy of other etiologies
(B), and seropositive chagasic (CC) indi-
viduals from Argentina (C) and Mexico
(D). High abundance proteins containing
sera fractions were run in the first dimen-
sion by isoelectric focusing on 11-cm
linear pH 4–7 IPG strips, and second
dimension was carried out by SDS-
PAGE on an 8–10% gradient gel. Shown
are Sypro Ruby-stained gel images. E,
protein spots, marked on C, that were
identified to be differentially expressed
by 2-fold in chagasic subjects were
submitted to MALDI-TOF MS analysis
(listed in Table II).
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trophils (ALB, C4B, CFB, F2, GC, GCNT1, IGHG1, IGHG3,
KNG1, PLG, PRL, and SERPING1), oxidative burst of granu-
locytes, cytotoxic reactions (IGHA1, IGHA2, IGHG1, IGKC,
and IGHG3), and aggregation of blood platelets (ALB, F2, GC,
KNG1, PLG, and SERPINC1). Functional analysis of the car-
diovascular system development and function network
merged with cardiovascular disease category annotated the
differentially expressed proteins to thrombosis (ALB, CFB, F2,
HRG, KNG1, PLG, and SERPINC1), angiogenesis (F2, HRG,
KNG1, MEF2C, PLG, PRL, SERPINC1, and VIM), and vaso-
dilatation (APOC3, F2, K2, KNG1, PLG, PRL, and VIM) of
blood vessel or aorta, increased permeability (C4B, F2, KNG1,
and SERPINC1) or formation (FGG, KNG1, MEF2C, MYH11,
PLG, and PRL) of blood vessels, capillary and endothelial
tubes, and muscle contraction (C4B, KNG1, MYH11, MYL2,
UTRN, and VCL). The differentially expressed proteins (n 
23) in lipid metabolism and molecular transport category were
functionally annotated to affect lipid quantity (ALB, APOC3,
CLU, F2, GC, F2R, KNG1, PLG, PRL, PVALB, SERPINC1, and
TTR) via altering lipid synthesis (ALB, CLU, CYP1B1, F2,
KNG1, PLG, POMC, and PRL) or degradation (ALB, APOC3,
CLU, PLG), and to lipid release (ALB, F2, KNG1, PLG, PRL,
SERPINC1, and VIM) or transport (ALB, APOC3, CLU, F2, and
GC). Further, we identified 30 differentially expressed proteins
that were linked to cell death and apoptosis (supplemental
Table S2). The top canonical pathway analysis identified sev-
eral differentially expressed proteins (ALB, AMBP, C1R, C4B,
C4BPA, CFB, CP, F2, FGG, HRG, ITIH2, PLG, SERPINA3,
SERPING1, TF, and TTR) that were indicative of the acute
phase response signaling pathway (supplemental Fig. S10)
and that can be induced in response to infection or triggered
by tissue injury and provide protection by using nonspecific
defense mechanisms.
Validation of Differentially Expressed Proteins in Chagas
Disease—To validate the T. cruzi-induced differential expres-
sion of sera proteins identified by PF2D/2D-GE and mass
spectrometry, we chose to perform ELISA with protein-spe-
cific antibody to detect the expression levels of VCL, MYL2,
VIM, and PLG in chagasic (n  35) and healthy subjects (n 
20) (Fig. 6). These data exhibited a substantially higher level of
VCL, MYL2, and PLG in seropositive chagasic patients com-
pared with normal healthy controls (p  0.001). We noticed
that 51% of the chagasic patients exhibited VCL levels
significantly higher than the meanseropositive values (mean
A450 nm, 0.372  0.114 versus 0.186  0.053; range, 0.240–
0.499 versus 0.101–0.412, seropositive versus seronegative,
p  0.001; Fig. 6A). Likewise, 56% of the chagasic patients
exhibited a significantly higher level of MYL2 than the
meanseropositive value (mean A450 nm, 0.329  0.101 versus
0.173  0.0181; range, 0.121–0.332 versus 0.204–0.423;
seropositive versus seronegative, p  0.0001; Fig. 6B). Fur-
ther, the sera level of PLG was significantly increased in 32%
of the chagasic patients (mean value, 216  33 versus 188 
40; range, 147–280 versus 100–220 g/ml; seropositive ver-
FIG. 5. Protein carbonyls detected in serum of chagasic subjects. A–C, high abundance proteins containing sera fractions (separated by
using the IgY-12 columns) from normal subjects (A), patients exhibiting cardiomyopathy of other etiologies (B), and seropositive chagasic
individuals (C) were run in the first dimension by isoelectric focusing on 11-cm linear pH 4–7 IPG strips. The strips were incubated with DNPH
to derivatize carbonyl proteins, and second dimension was carried out by SDS-PAGE on an 8–10% gradient gel. Shown are the representative
images of Western blotting with anti-DNPH antibody. Respective Sypro Ruby-stained gel images are shown in Fig. 4. D, for the detection of
protein carbonyls in low abundance sera protein fractions, PF2D second dimension fractions were derivatized with DNPH and then subjected
to fourth dimension fractionation on an 8% polyacrylamide gel. Western blotting was performed with anti-DNPH antibody. The Coomassie
Blue-stained image is shown as an inset in Fig. 3. Carbonyl proteins were identified by MALDI-TOF MS analysis (listed in Tables I and II).
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sus seronegative, p  0.0001; Fig. 6D). The sera levels of VIM
were increased in 10% of the seropositive individuals as
compared with those in normal healthy controls (mean A450 nm,
0.329  0.101 versus 0.173  0.0181; range, 0.204–0.423
versus 0.121–0.332; seropositive versus seronegative; Fig.
6C); however, these results were not statistically significant.
Seronegative patients with cardiac symptoms caused by
other etiologies (n  25) exhibited a marginal, but not statis-
tically significant, increase in VCL, and no increase in MYL2
and VIM levels in sera when compared with these levels in
normal controls (data not shown). Together, these data vali-
dated the PF2D/mass spectrometry results and led us to
suggest that the sera levels of VCL, MYL2, and PLG will be
useful indicators of disease and disease severity in human
chagasic patients.
DISCUSSION
In this study, we have developed a comprehensive serum
proteome profile of chagasic human patients by utilizing a
combination of PF2D ProteomeLab and traditional 2D-GE
techniques. Parasite persistence and oxidative damage in the
heart are known to be of pathological significance during
Chagas disease (32, 33). To examine this, we collected sera of
clinically diagnosed cardiomyopathy patients with or without
Chagas disease and compared with normal healthy controls
from the same geographic area to identify the disease-spe-
cific serum proteome changes. We identified 14 proteins that
were differentially expressed in sera of other cardiomyopathy
patients, and 80 and 26 proteins that were differentially ex-
pressed or oxidized, respectively, in the sera of chagasic
patients. Functional and network analysis assigned a majority
of the differentially expressed proteins to molecular pathways
associated with inflammatory responses, lipid metabolism,
and molecular transport, contributing to cell death and car-
diovascular disease, i.e., myocardial infarction, embolism,
and hypertension, in chagasic patients. Canonical pathway
analysis verified the disease association to dysregulation of
the acute phase response signaling pathway. To the best of
our knowledge, this is the first study demonstrating the serum
oxidative and inflammatory response profile, and serum de-
tection of cardiac proteins parallels the pathologic events
contributing to Chagas disease development. Furthermore,
we believe the findings have a potential utility in diagnosing
disease severity and designing suitable therapy for manage-
ment of human chagasic patients.
The PF2D system represents a promising tool for proteomic
mapping because of its superior reproducibility, sensitivity,
and automation capacity over the classical 2D gel electropho-
resis, as demonstrated by a number of studies in various cell
models and tissue types (34–38). The present work is the first
demonstration of using such a protein fractionation technique
for a large scale profiling of the serum proteome of chagasic
patients. The 12 major proteins accounting for 90% of the
serum protein interfere with the detection of low abundance
potential biomarker proteins. The IgY LC10 chromatography
removed 90–95% of the high abundance proteins allowing
enrichment of low abundance proteins, yet proteome analysis
of high abundance protein fractions by 2D-GE demonstrated
that some of the low abundance proteins partitioned with high
abundance protein sera fractions (Table II), likely because of
binding of low abundance proteins to high abundance pro-
teins. Overall, the PF2D analysis of low abundance protein
fractions yielded highly reproducible data, leading to the iden-
tification of 80 disease-associated low abundance proteins
(p  0.001). Of these, some proteins were identified as differ-
entially expressed in multiple groups. For example, C4BPA
was identified to be differentially expressed in normal as well
as chagasic patients because of the difference in oxidation;
PCID2 was identified to be increased in the sera of chagasic
and other cardiomyopathy patients as compared with normal
controls, and HRG, SERPINA3, and NUMA1 were identified in
different second dimension fractions of chagasic patients (Ta-
ble I). A similar anomaly has been reported in previous pro-
teomic studies in which the PF2D system was used (39–41).
Several factors including time-based rather than peak-based
FIG. 6. Validation of expression profile of selected proteins in
chagasic sera. Whole sera samples from normal and chagasic sub-
jects were subjected to ELISA analysis by using antibodies against
VCL (A), cardiac specific MYL2 (B), VIM (C), and PLG (D). Standard
deviation for triplicate observations for each sample was 12%.
Shown is box plot of ELISA data, graphically depicting the values for
seronegative and seropositive groups. The horizontal lines of the box
(bottom to top) depict the lower quartile (Q1, cuts off lowest 25% of
the data), median (Q2, middle value), and upper quartile (Q3, cuts off
the highest 25% of the data). The lower and upper whiskers depict the
smallest and largest non-outlier observations, respectively, and the
solid dots represent the outliers. The spacing between the different
parts of the box indicates the degree of dispersion (spread). Conc,
concentration; OD (450 nm), A450 nm.
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fractionation during second dimension chromatography and
post-translational modifications, e.g., protein carbonylation,
phosphorylation resulting in a shift in their pI or molecular
weight, may have contributed to variance in partitioning and
detection of proteins.
IPA is highly curated and comprehensive software used for
the integration of proteins into networks and pathways with
biological meaning. Network analysis of serum proteome pro-
files of chagasic patients identified four major subnetworks
linked to the host response to T. cruzi infection and disease
development, three of which were directly indicative of alter-
ations in gene expression, cellular assembly, and cardiovas-
cular system development and function leading to cardiovas-
cular disease (supplemental Table S1). Functional annotation
associated 29 of the differentially expressed proteins to the
inflammatory response category (supplemental Table S2),
many of which are known to affect activation of leukocytes,
quantity of phagocytes, movement and migration of phago-
cytes, and aggregation of blood platelets. The presence of a
mixed host response, i.e., attempt to decrease (e.g., GCNT1,
SERPINA3, SERPIC1, and SERPING1), as well as increase
(e.g., F2, GC, IGHA1, IGHA2, IGHG3, IGKC, KNG1, and PRL)
immune responses was evident, which may indicate persis-
tence of inflammation, known to be of pathological signifi-
cance in Chagas disease (42, 43). Overall, it appeared that
increased complement activation (C4A/C4B, CLU, and KNG1)
and activation and proliferation of phagocytes (F2, GC, KNG1,
MYH11, PLG, and TF) and leukocytes (C4B, F2, GC, IGHG3,
KNG1, PLG, and PRL) were followed by attempts to control
cell movement or migration of immune cells (PLG, SERPINA3,
SERPINC1, and SERPING1) to prevent tissue damage caused
by inflammatory cytotoxic reactions. It is important to note
that of the 29 differentially expressed inflammation-associ-
ated proteins (supplemental Table S2), seven proteins (ALB,
BCL2A1, IGHG3, IGKC, SERPINA3, SERPINC1, and TF) were
carbonylated (Tables I and II) in chagasic serum, which indi-
cates that oxidative stress plays an important role in modu-
lating the host immune response against T. cruzi. Other stud-
ies have demonstrated that ROS elicit inflammatory cytokines
(e.g., TNF-, IFN-, and IL-1) in cardiomyocytes infected by
T. cruzi (44, 45). Inflammatory pathology was controlled in
chronically infected experimental animals and human patients
by enhancing the antioxidant status, which was also benefi-
cial in preserving cardiac function during Chagas disease (15,
16, 46, 47). Our recent observations indicate that the mito-
chondrial release of ROS caused by electron transport chain
dysfunction and enhanced release of electrons to molecular
oxygen is the primary source of oxidative stress in the heart
(13). Further studies will be required to delineate the signifi-
cance of mitochondrial ROS and classical ROS producers,
i.e., NADPH oxidase and myeloperoxidase, known to play an
important role in parasite control during the acute phase of
infection (24, 49, 81), in elicitation of inflammatory responses
during Chagas disease.
Twenty-three of the differentially expressed proteins in cha-
gasic serum were allotted to the lipid metabolism/molecular
transport category (supplemental Table S2). The expression
levels of several of the proteins including ALB, APOC3, F2,
F2R, KNG1, POMC, PRL, and SERPINC1 that increase quan-
tity, production, release, and transport of lipids, specifically
arachidonic acid and prostaglandins, were deregulated in
chagasic patients (Tables I and II). Arachidonic acid is the
precursor for prostaglandins, which function as autocrine and
paracrine mediators that act upon several cell types including
platelets and endothelium (50). Heightened platelet reactivity
and endothelial cell dysfunction associated with an increased
release of 6-keto-prostaglandin F1 from endothelium during
T. cruzi infection is documented (51) and supported by our
observation of the increased expression of several proteins
(ALB, F2, GC, KNG1, and SERPINC1) activated to control
blood platelet aggregation. Host as well as parasite-derived
prostaglandins have been implicated in the pathogenesis of
Chagas disease (52), and eicosanoids present during acute
infection have been suggested to act as immunomodulators
(52) aiding the transition to and maintenance of the chronic
phase of the disease (53, 54). Treatment with cycloxygenase
2 inhibitors (e.g., aspirin) has been shown to reduce cardiac
damage (54) in chagasic experimental models. Our data in this
study validate the observations made in experimental models
and allow us to propose that dysregulation of lipid mediators
and inflammation are interlinked pathological events during
human Chagas disease, to be further validated in future
studies.
When categorized in relation to disease severity, it became
apparent that chagasic patients exhibited proteome signa-
tures of cardiovascular disorders (CFB, CTTN, DIP2A, GMDS,
HRG, KIAA1370, MYH11, OSBPL8, PDE4A, PLG, SERPINC1,
TRIB1, and VCL) associated with myocardial ischemia (DIP2A,
GMDS, KIAA1370, MYH11, OSBPL8, PDE4A, PLG, SER-
PINC1, and VCL) and cardiomyopathy (PLG, TRIB1, and VCL).
The proteomic signature of merged networks of Chagas dis-
ease positioned PLG (plasminogen) and F2 (prothrombin) at a
central nodal position (supplemental Fig. S9.5) with connec-
tivity to numerous proteins indicative of thrombosis (ALB,
CFB, F2, HRG, KNG1, PLG, and SERPINC1), angiogenesis
(F2, HRG, KNG1, MEF2C, PLG, PRL, and SERPINC1), vaso-
dilatation of blood vessel or aorta (APOC3, F2, K2, KNG1,
PLG, PRL, and VIM), increased permeability of blood vessel
and endothelial tubes (C4B, F2, KNG1, and SERPINC1), and
muscle loss of contraction (C4B, KNG1, MYH11, MYL2,
UTRN, and VCL). Moreover, indicators of platelet aggregation
(ALB, F2, GC, KNG1, PLG, and SERPINC1) and complement
activation (C4B, CFB, CLU, IGHG1, and KNG1), as well as
acute phase response signaling (ALB, AMBP, TTR, CFB,
HRG, TF, ITIH2, C4BP, C4, FGG, CP, SERPINA2, SERPING1,
and SERPINF), were linked to PLG and/or F2 nodes. PLG,
when activated to function as serine protease (plasmin), di-
rectly attacks fibrin blood clots (55). Prothrombin (coaglulation
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factor II) is proteolytically activated to form thrombin that acts
as a trypsin-like serine protease. F2 complements PLG func-
tion, contributing platelet activation and aggregation via acti-
vation of protease-activated receptors on the cell membranes
and catalyzing polymerization of soluble fibrinogen into insol-
uble fibrin (56). A deficiency of, as well as up-regulation of,
PLG and F2 beyond physiological levels can lead to multiple
pathological outcomes, including thrombosis caused by par-
tial or inadequate degradation of blood clots, defective wound
healing, and excessive bleeding (55–57). Plasmin is postu-
lated to influence the progression of cardiovascular diseases
through activation of collagenases and matrix metalloprotei-
nases and resultant degradation of matrix proteins (58) and
has also been implicated in metabolic syndrome (59). PLG,
F2, and their receptors are also closely linked to regulation of
cardiovascular inflammatory responses and have been sug-
gested by others to influence cell migration through regulation
of growth factor and chemokine pathways and acute phase
response signaling through activation of C3 component of
complement system (60). Plasmin-mediated fibrin degrada-
tion products have vascular permeability-inducing effects and
are considered a cardiovascular disease risk factor in aging
(61). An increase in thrombolytic risk factors is documented in
chagasic patients (62). Our network analysis provides the first
indication of the central role of PLG and F2 in Chagas disease.
Dissection of the mechanisms altered by PLG and F2 in an
effort to understand their roles in vivo represents a future
challenge in unraveling the pathogenesis of Chagas disease.
In prior studies, we and others have documented oxidative
stress pathogenesis in experimental models of Chagas dis-
ease (32, 33) and shown that enhancing antioxidant status
was beneficial in controlling cardiac tissue damage and sub-
sequent loss of contractile function (16). In this study, five
proteins associated with free radical scavenging, i.e., ALB,
CLU, CP, F2, and PRODH were identified, all of which were
either depressed or oxidized in chagasic patients. CLU (Clus-
trin) is suggested to prevent cell death and the associated
cytotoxicity of superoxide (63), and CP (ceruloplasmin) is
related to reduction of superoxide through its antioxidant
properties independently of its function in iron metabolism
(64). A positive correlation between ceruloplasmin and the
incidence of atrial fibrillation has been documented in a pop-
ulation-based cohort study (65). PRODH (proline dehydrogen-
ase) modulates the intracellular redox environment and pro-
tects mammalian cells against oxidative stress (66). Albumin
is present in large amounts in plasma and sera, and 70–80%
of Cys34 in albumin contains a free sulfhydryl group. Through
the reduced Cys34, ALB is able to scavenge hydroxyl radicals
(67). Cys34 and Met residues (six) are also oxidation-sensitive
amino acids in ALB. Increased glycation of ALB occurs in
diabetes mellitus, which is one of the pathological conditions
associated with an early occurrence of vascular complications
(68). Our observation of the decreased expression or in-
creased oxidation of these proteins in chagasic patients pro-
vides the proteomic signature of compromised antioxidant
status.
Four proteins (VIM, MYL2, MYH11, and VCL) directly linked
to cardiac muscle functions deserve to be further discussed.
VIM is a member of the intermediate filament network, and
along with microtubules and actin microfilaments, it plays an
important role in maintaining cell shape and integrity of cyto-
plasm and stabilizing cytoskeletal interactions (69). Vimentin
is also shown to be localized in common carotid artery and
heart valves and serves as a target antigen of peripheral and
heart-infiltrating T cells during valvular disease (70). The in-
creased detection of VIM in the heart is indicative of the
occurrence of a fibrotic process, because infiltrating fibro-
blasts replace damaged cardiomyocytes in disease condi-
tions (70) and has been identified by proteomic inventory of
myocardial proteins in patients with Chagas disease (71). The
increased plasma detection of VIM in 10% of the seropositive
chagasic patients may be indicative of its significance in
relation to disease severity and requires further investigation
in large cohort studies. MYL2 is a cardiac-specific protein.
MYL2 dimerizes with cardiac myosin  (or slow) heavy chain,
and its phosphorylation by Ca2 triggers cardiac contrac-
tions. Mutations inMYL2 or abnormalities in MYL2 expression
are associated with cardiomyopathy (72), heart failure (73), left
ventricular hypertrophy (74), and familial hypertrophy (75).
MYH11 is a smooth muscle myosin belonging to the myosin
heavy chain family. It functions as a major contractile protein,
utilizing the energy of ATP hydrolysis to move actin filaments
and produce muscle force. MYH11 mutations are docu-
mented to result in a distinct aortic and occlusive vascular
pathology (76). Deletion, splicing, and mis-sense mutations in
MYH11 have been identified in patients with familial thoracic
aortic aneurysm and dissections with patent ductus arteriosus
type 4, which is one of the most severe cardiovascular con-
ditions in adults (77). Studies have shown that MYH11
heterozygous mutations lead to early severe decrease in the
elasticity of the aortic wall, a finding consistent with the role of
smooth muscle cells in maintaining the mechanical properties
of the thoracic aorta (78). Vinculin plays a pivotal role in cell
adhesion and migration by providing the link between the
actin cytoskeleton and the transmembrane receptors integrin
and cadherin (79). VCL is a cytoskeletal protein associated
with cell to cell and cell-matrix junctions, where it is thought to
function as one of several interacting proteins involved in
anchoring F-actin to the membrane. Defects in VCL are the
cause of dilated cardiomyopathy (80). The absence of VCL
demonstrates a decrease in the spreading of cells that was
accompanied by reduced stress fiber formation and restored
by its overexpression (48). The sera release of MYL2 and
MYH11 and up-regulation of VCL provide a comprehensive
set of biomarkers of cardiac muscle injury and development of
clinical Chagas disease in human patients.
In summary, we were successful in employing PF2D and
2D-GE to resolve low abundance and high abundance sera
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proteins for the development of a proteomic signature of
Chagas disease. The functional analysis of differentially ex-
pressed/oxidized sera proteins suggested that dysregulated
inflammation/acute phase response signaling and lipid me-
tabolism relevant to production of prostaglandins were asso-
ciated with cell death and cardiovascular disease in chagasic
patients. Further studies are required to investigate the causal
and mechanistic relationship of altered lipid metabolism in
Chagas disease. Our ability to detect significantly higher lev-
els of MYL2, VCL, and PLG in the sera of chagasic subjects
indicates that these protein biomarkers are independent of
the parasite lineage and the genetic or ethnic background of
the host and thus have potential utility for diagnosis of cardiac
muscle injury and development of clinical Chagas disease in
human patients. These results provide an impetus for bio-
marker validation in large cohorts of clinically characterized
chagasic patients.
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